Found 6 articles for: "Guselkumab"

Two-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis Patients

August 2025 | Volume 24 | Issue 8 | Original Article | 762 | Copyright © August 2025

Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc Analyses

February 2025 | Volume 24 | Issue 2 | Original Article | 196 | Copyright © February 2025

Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study

August 2024 | Volume 23 | Issue 8 | Original Article | 632 | Copyright © August 2024

Single-Centre Real-Life Experience of Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis

August 2022 | Volume 21 | Issue 8 | Original Article | 864 | Copyright © August 2022

The efficacy of guselkumab has been demonstrated in randomized controlled trials, but real-life data are still missing. This study presents a single-center real-life experience in treating moderate-to...
Read More

Characteristics of Patients Initiating Guselkumab for Plaque Psoriasis in the Symphony Health Claims Database

October 2021 | Volume 20 | Issue 10 | Features | 1127 | Copyright © October 2021

Guselkumab is approved by the Food and Drug Administration for the treatment of moderate-to-severe plaque psoriasis. However, characteristics of patients initiating guselkumab in a real-world setting ...
Read More

Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2

August 2021 | Volume 20 | Issue 8 | Original Article | 855 | Copyright © August 2021

Background: Anti-interleukin (IL)-17 biologic agents used to treat psoriasis are associated with onset/exacerbation of inflammatory bowel disease (IBD). Objectives: To determine the incidence of IBD o...
Read More